北京时间8月15日早晨，巴菲特旗下伯克希尔·哈撒韦公司披露了最新的二季度持仓报告美 股持仓情况，市场颇为关心的苹果减持和"神秘持仓"终于曝光。其中，新建仓标的涉及医 疗、钢铁、房地产等板块。 今年二季度，伯克希尔减持了苹果和美国银行；新买入了6只股票，包括：联合健康 （UNH）、纽柯钢铁（NUE）、莱纳建筑（LEN）、霍顿房屋（DHI）和拉马尔户外广告 （LAMR）、安朗杰（ALLE）。 相关新建仓标的在盘后显著拉升，联合健康、纽柯钢铁等一度涨超8%。 买入医疗、钢铁、地产等 伯克希尔在一季度留下的"神秘建仓"悬念，在 二季度持仓报告 揭晓了。 此前，市场猜测这一"神秘"投资标的很可能是工业板块公司，总投资额或接近50亿美元。 有关"神秘持仓"的线索源于伯克希尔的季度财报。公司 二季报 未详细披露苹果等重仓股之 外的小规模投资，而是将股票投资分为金融、消费品和"商业、工业及其他"三个大类。 伯克希尔 二季报 显示，今年第一季度，伯克希尔在"商业、工业及其他"类别的成本基础增 加了近20亿美元，但5月提交的一季度 持仓 报告未披露相应的大型工业股购买。到了第二 季度，该类别成本基础进一步增加了28亿美元，两个季 ...

ROCHESTER, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2025 Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 in Boston, MA. The presentation is scheduled to begin at 3:45 p.m. ET and is expected to cover the company’s fina ...

ROCHESTER, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2025 Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 in Boston, MA. The presentation is scheduled to begin at 3:45 p.m. ET and is expected to cover the company’s fina ...

#全球投资名人堂沃伦·巴菲特私募排排网专栏 从20世纪50年代投身投资领域开始，巴菲特就缔造了一段难以复制的神话，收获了"股神""投资之神""奥马哈的先知"等诸多美誉，更是全球唯一一位仅靠投 资便登顶世界首富的人。今天，让我们一同走进巴菲特的世界，探寻他的成功密码。 前言： 8月2日，巴菲特旗下的伯克希尔·哈撒韦公司披露，其对食品巨头卡夫亨氏的投资进行了高达38亿美元的资产减记。这使得该项投资的账面价值骤降至84亿 美元，较2017年底的逾170亿美元大幅缩水。 账面价值的暴跌似乎坐实了外界对该交易的悲观评价。然而，英国《金融时报》的分析揭示了一个关键转折：得益于巴菲特在交易谈判中争取到的精妙条 款，即便在这场公认的投资"滑铁卢"中，他实际上已悄然实现了近60%的盈利。当市场还在为表面的巨额亏损叹息时，股神早已凭借交易架构的优势锁定了 丰厚回报。 一项投资在短短几年内账面价值惨遭"腰斩"，这通常标志着彻底的失败——但主角若是沃伦·巴菲特，结局往往出人意料。 巴菲特从小就乖巧懂事，仿佛特别能体谅父母的艰辛。当父母忙碌时，给他一个简单的玩具，如牙刷或布偶，他就能安静地玩上半天。这份安静懂事，对霍 华德和利拉来说， ...

Core Viewpoint - Constellation Brands reported disappointing Q1 fiscal 2026 results, with both sales and earnings missing estimates, primarily due to weak consumer demand influenced by socioeconomic factors [3][4]. Financial Performance - Comparable earnings per share (EPS) for Q1 were $3.22, down 10% year over year, missing the Zacks Consensus Estimate of $3.38. Reported EPS was $2.90, a 39% decline year over year [4]. - Net sales fell 5.5% year over year to $2.52 billion, also missing the Zacks Consensus Estimate of $2.57 billion [4]. - The beer segment's sales decreased 2% year over year to $2.23 billion, with a shipment volume decline of 3.3% [5]. - The wine and spirits segment saw a significant sales drop of 28% year over year to $280.5 million, driven by a 30.4% decline in shipment volumes [6]. Margin Analysis - Comparable operating income was $810 million, down 11% from the prior year, attributed to declines in both beer and wine & spirits segments [7]. - Operating income for the beer segment fell 5% year over year to $873.4 million, with an operating margin contraction of 150 basis points to 39.1% due to increased costs [8]. - The wine and spirits segment reported an operating loss of $6 million, a significant decline from an operating income of $59.7 million in the previous year [9]. Financial Position - As of May 31, 2025, cash and cash equivalents were $73.9 million, long-term debt was $9.8 billion, and total shareholders' equity was $7.3 billion [10]. - The company generated an operating cash flow of $637.2 million and an adjusted free cash flow of $444.4 million for Q1 [10][11]. Future Outlook - Constellation Brands forecasts operating cash flow of $2.7-$2.8 billion and free cash flow of $1.5-$1.6 billion for fiscal 2026, with planned capital expenditures of $1.2 billion [12]. - The company anticipates organic net sales for fiscal 2026 to range from a decline of 2% to an increase of 1%, with the beer segment expected to grow 0-3% and the wine and spirits segment to decline 17-20% [13]. - Comparable EPS guidance for fiscal 2026 is set at $12.60-$12.90, with reported EPS expected to be $12.07-$12.37 [15].

Group 1 - The S&P 500 index is reaching record highs, indicating strong market performance, but there is a caution that significant optimism is already reflected in the index [2] - A limited number of stocks, such as NVIDIA, are driving the index's performance, suggesting a concentration of gains among a few companies [2] Group 2 - iREIT+HOYA Capital focuses on income-producing asset classes, aiming for sustainable portfolio income, diversification, and inflation hedging [1]

Group 1 - Constellation Brands (STZ) is a leading alcoholic beverage producer known for high-quality brands, particularly Corona, which is often rated as the most valuable beer brand [1] - The company has a diverse portfolio that includes various commodities and sectors, showcasing its extensive research experience in industries such as metals, mining, consumer discretionary, REITs, and utilities [1] Group 2 - The analyst has over 10 years of experience researching companies, estimating in-depth research on over 1000 companies across multiple sectors [1]

Core Viewpoint - Constellation Brands and Altria are both considered stable blue chip stocks, but Altria has outperformed Constellation significantly over the past three years, raising questions about future investment potential [1][2]. Constellation Brands - Constellation Brands generates most of its revenue from its beer business, with popular brands like Modelo and Corona, and a smaller portion from wine and spirits [4]. - The company faces three major challenges: declining beer consumption among younger consumers, decreasing sales of lower-end wines, and increased costs due to tariffs on imported Mexican beers [5][6]. - Analysts expect Constellation's revenue to decline from $10.2 billion in 2024 to $9.9 billion in 2027, while its earnings per share (EPS) is projected to grow at a compound annual growth rate (CAGR) of 7% [8]. - Despite a low valuation at 14 times forward earnings and a forward yield of 2.5%, the lack of near-term catalysts makes it an unappealing investment [9]. Altria - Altria primarily generates revenue from its Marlboro cigarettes and has a strong domestic focus, which protects it from tariffs and foreign-exchange issues [10][11]. - The company has been countering declining smoking rates by raising cigarette prices, cutting costs, and expanding its smokeless product portfolio through investments and acquisitions [12]. - Following a setback with its investment in Juul, Altria acquired Njoy for $2.8 billion in 2023, which is expected to boost EPS starting in 2026 [13]. - Analysts predict Altria's revenue will dip slightly from $20.4 billion in 2024 to $20.2 billion in 2027, but its EPS is expected to grow at a steady CAGR of 5% from 2025 to 2027 [14][15]. - Altria's stock is considered cheap at 12 times forward earnings, with a substantial forward yield of nearly 7%, making it a more stable investment compared to Constellation [15]. Investment Recommendation - Altria is viewed as the better investment option due to its more stable business model, larger dividend, and lower valuation multiple compared to Constellation Brands [16].

Core Viewpoint - Constellation Brands, a major player in the beer industry, is facing challenges but has potential for long-term growth, particularly due to demographic shifts and significant investment from Warren Buffett [1][8]. Financial Performance - Constellation Brands reported a 5.5% drop in total revenue last quarter, attributed to industry-wide beer sales declining by 4.7% and specific pressures on its Hispanic consumer base [3][4]. - The company missed expectations on both sales and adjusted earnings per share (EPS), yet maintained its full-year adjusted EPS guidance for fiscal 2026, which positively influenced analysts' price targets [4]. Market Position and Analyst Sentiment - Constellation's beer sales only declined by 2%, indicating a gain in market share despite overall industry softness [3]. - Analysts have raised their price targets for Constellation, with a consensus target of approximately $215, suggesting a potential upside of over 25% from the current price of $169.31 [5][6]. - The average updated price target after the latest earnings report is $191, indicating a more modest upside of around 12% [6]. Investment Insights - Warren Buffett's investment strategy reflects a bullish outlook on Constellation, having increased his holdings significantly, which suggests confidence in the company's long-term value [5][9]. - Demographic trends indicate that the Latino and Hispanic population in the U.S. is expected to grow significantly from 2030 to 2060, providing a structural tailwind for Constellation's business [8][9].

Group 1: Dividend-Paying Stocks Performance - Dividend-paying stocks in the S&P 500 index delivered an average annualized return of 9.2% over the 50-year period ending in 2024, compared to 4.3% for non-dividend stocks [3] - Novo Nordisk and Constellation Brands are highlighted as dividend-paying stocks that have seen significant price declines but are expected to rebound [4] Group 2: Novo Nordisk Analysis - Novo Nordisk's stock price has dropped over 50% in the past year, yet its earnings per share have increased by 154% over the last five years, indicating strong underlying performance [5] - Analysts project a consensus price target above $97 per share for Novo Nordisk, suggesting a potential 40% increase in the next 12 months [6] - The company has increased total dividends per share by 173% from 2019 to 2024, with a potential yield of 1.8% for investors buying at recent prices [7] - First-quarter sales of its obesity drug, Wegovy, surged by 65% to $2.9 billion, contributing to an overall revenue increase of 18% at constant exchange rates [8] - The main patent for semaglutide, Novo Nordisk's leading drug, does not expire until 2032, allowing for continued market exclusivity [10] Group 3: Constellation Brands Analysis - Constellation Brands' stock has fallen by about one-third in the past year, but analysts expect a rebound with an average price target of $202, implying a 17% gain [11] - The company has consistently raised its dividend since 2015, with a current yield of 2.4% and a 229% increase in dividend payments over the past 10 years [12][13] - Constellation's beer business is gaining market share, and despite potential challenges from new tariffs on imports from Mexico, it remains the sole distributor of popular brands like Modelo and Corona [14][15]